Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)

EGFR-TKI Resistant Mutation Clinical Trial

Official title:
High Dose Weekly Use First-generation EGFR-TKI Instead of Daily Regular Dose in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)

Status Completed

Clinical Trial Summary

EGFR-TKI is the main is the first line therapy for local advanced or metastatic non-small cell lung cancer with EGFR gene mutation. The median progression free survival time is around 11 months with the first generation EGFR-TKI. Patients with acquired resistance with first generation EGFR-TKI usually with EGFR exon 20 mutation (T790M). Change the drug administration maybe prolong patients PFS and evently prolong OS.

Clinical Trial Description

1st generation EGFR-TKI has reversible binding to EGFR, it also bind to T790M in a high dose which is account about 60% patients acquired resistance to the drug. Resistance patients may be benefit to a bolus drug use to block T790M gene. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02575560
Study type	Observational
Source	Qingdao Central Hospital
Contact
Status	Completed
Phase	N/A
Start date	October 1, 2015
Completion date	December 31, 2017

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06071013` - Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients	Phase 1/Phase 2
Recruiting	`NCT05598528` - Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
Recruiting	`NCT01994057` - A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
Recruiting	`NCT05256290` - Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations	Phase 1/Phase 2
Not yet recruiting	`NCT02661009` - Human EGFR Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method)	N/A
Not yet recruiting	`NCT02972333` - Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M	Phase 3
Recruiting	`NCT06363734` - Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial	Phase 2